News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) VELCADE Improved Outcomes in Multiple Myeloma Patients After Transplant in Nordic Myeloma Study



5/6/2011 9:15:47 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported the presentation of results of a randomized Phase III trial that investigated the effect of consolidation with single-agent VELCADE® (bortezomib) for Injection in newly diagnosed multiple myeloma (MM) patients after autologous stem cell transplant (ASCT). The study showed that consolidation with VELCADE led to significant improvements in response rates and progression-free survival, while the overall survival rate was 87 percent in both arms after a median follow-up of 27 months. These data were presented at the 13th International Myeloma Workshop, held May 3-6 in Paris, France.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES